4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $10.90, for a total transaction of $17,821.50. Following the completion of the sale, the insider directly owned 3,594 shares of the company’s stock, valued at approximately $39,174.60. This represents a 31.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Scott Bizily also recently made the following trade(s):

• On Monday, November 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.59, for a total transaction of $17,314.65.
• On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $32,136.00.
• On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.17, for a total transaction of $16,627.95.
• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total value of $19,256.00.

4D Molecular Therapeutics Stock Down 0.1%

FDMT opened at $8.68 on Friday. 4D Molecular Therapeutics, Inc. has a 52 week low of $2.23 and a 52 week high of $12.34. The stock has a market cap of $495.89 million, a PE ratio of -2.31 and a beta of 2.96. The business has a 50 day moving average of $10.68 and a 200-day moving average of $7.50.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. Equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics in the first quarter worth $39,000. Wexford Capital LP purchased a new position in 4D Molecular Therapeutics in the 3rd quarter worth about $41,000. Los Angeles Capital Management LLC purchased a new position in 4D Molecular Therapeutics in the 2nd quarter worth about $42,000. Quadrature Capital Ltd bought a new position in 4D Molecular Therapeutics during the 2nd quarter valued at about $42,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Leerink Partners restated an “outperform” rating and issued a $17.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Chardan Capital restated a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Barclays dropped their target price on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.70.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.